Compare Vanguard Total World Stock Index Fund ETF (VT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total World Stock Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Total World Stock Index Fund ETF trades at $159.83 (market cap $101.70B), while GeneDx Holdings Corp trades at $67.69 (market cap $2.02B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 50.3× GeneDx Holdings Corp's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total World Stock Index Fund ETF for 53 Days and GeneDx Holdings Corp for 19 Days on average.
| VT | WGS | |
|---|---|---|
Market Cap | $101.70B | $2.02B |
Volume | 1,783,794 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $162.39 | $167.51 |
52-Week Low | $134.19 | $34.51 |
Typical Hold Time | 53 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Total World Stock ETF (VT) trades at $159.84, up 0.13% with a bearish technical signal from moving averages. The ETF provides exposure to over 9,700 global stocks with a 0.06% expense ratio, though key financial ratios remain unavailable. Recent news highlights VT's diversification benefits and competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF.
VT offers broad global diversification but faces headwinds from technical bearish signals and expense ratio competition. The outlook remains neutral with institutional interest mixed; risks include market volatility and geopolitical factors. Long-term investors may value its comprehensive market coverage despite near-term technical weakness.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
